Alvotech up on partner's application for biosimilar candidate's approval

Alvotech SA

17/10/2022 16:55

** Shares of biotech firm Alvotech SA  ALVO.O  rise as much
as 7% to $7.3 
    ** Co's commercialisation partner, Fuji Pharma, has
submitted a marketing application in Japan for the companies’
first biosimilar candidate  urn:newsml:reuters.com:*:nGNX10TfN9
    ** The exclusive partnership agreement was first announced
by Alvotech and Fuji in November 2018, covering six proposed
biosimilars to be developed and manufactured by Alvotech, and
commercialized by Fuji in Japan
    ** Stock flat YTD
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))